|
As previously announced, for 2014, GlaxoSmithKline (LSE:GSK) will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area that identifies revenues from an Established Products Portfolio as a new segment. This new segment comprises a portfolio of over 50 tail brands.
GSK has also announced its intention to report core results performance for 2014 measured against 2013 core results excluding the results attributable to divestments completed during 2013. In addition to reporting core results, GSK will continue to report its total results measured against 2013 total results.
The revised reporting approach reflects the financial information provided to the Chief Executive Officer and the responsibilities of the Corporate Executive Team (CET).
In addition, the classification of certain products has been changed in 2014, including:
|
|
|
·
|
The transfer of the OTC dermatology brands acquired with the Stiefel business from the Pharmaceuticals and Vaccines business to the Consumer Healthcare business in the majority of emerging markets;
|
|
·
|
The combination of certain previous therapeutic categories into a new therapeutic category presentation that reflects the key areas of focus for the business and the impact of the transfer of the majority of the brands in some therapeutic areas into the new Established Products Portfolio;
|
|
·
|
The transfer of the OTC vitamins brands from inclusion under the Wellness category in Consumer Healthcare to inclusion under the Nutrition category.
|
|
In 2014, GSK also intends to report Pharmaceuticals and Vaccines turnover by product for the Japan segment. The previous EMAP segment is now named Emerging Markets.
In order to assist future comparability with historical data, for each quarter since the period ended 31 March 2013, and for the full years 2012 and 2013, this release includes the following information presented on a like-for-like basis with the classifications that will be reported in 2014:
· Core results excluding the results attributable to divestments completed during 2013;
· Pharmaceuticals and Vaccines turnover by product and region (excluding turnover attributable to divestments completed during 2013);
· Consumer Healthcare turnover by category and region (excluding turnover attributable to divestments completed during 2013);
· CER growth rates have been calculated for 2013 excluding the impact on the growth rate of the divestments completed in 2013 but including the impact of divestments completed in earlier periods.
An Excel version of this data will be available on www.gsk.com/investors.
|
|
|
GSK enquiries:
|
|||
|
UK Media enquiries:
|
David Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
US Media enquiries:
|
Stephen Rea
|
+1 215 751 4394
|
(Philadelphia)
|
|
Melinda Stubbee
|
+1 919 483 2510
|
(North Carolina)
|
|
|
Analyst/Investor enquiries:
|
Ziba Shamsi
|
+44 (0) 20 8047 5543
|
(London)
|
|
Tom Curry
|
+1 215 751 5419
|
(Philadelphia)
|
|
|
Gary Davies
|
+44 (0) 20 8047 5503
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Lucy Singah
|
+44 (0) 20 8047 2248
|
(London)
|
|
CER growth
In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period.
Core results
Core results exclude the following items from total results: amortisation and impairment of intangible assets (excluding computer software) and goodwill; major restructuring costs, including those costs following material acquisitions; legal charges (net of insurance recoveries) and expenses on the settlement of litigation and government investigations, and acquisition accounting adjustments relating to the consolidation of material acquisitions, disposals of associates, products and businesses, other operating income other than royalty income and other items, together with the tax effects of all of these items. GSK believes this approach provides a clearer view of the underlying performance of the core business and should make the Group's results more comparable with the majority of its peers.
Reconciliations of core results as previously reported to total results for 2013 have been included in an appendix to this document.
Brand names and partner acknowledgements
Brand names appearing in italics throughout this document are trademarks of GSK or associated companies or used under licence by the Group.
This Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The information for 2013 has been derived from the full Group accounts published in the Annual Report 2013.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.
|
|
Registered in England & Wales:
No. 3888792
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
Group turnover by segment
|
2013
|
Q4 2013
|
|||
|
-----------------------------------
|
-----------------------------------
|
||||
|
£m
|
Growth
CER%
|
£m
|
Growth
CER%
|
||
|
------------
|
------------
|
------------
|
------------
|
||
|
Pharmaceuticals and Vaccines
|
|||||
|
-
|
US
|
5,817
|
4
|
1,514
|
11
|
|
-
|
Europe
|
4,226
|
3
|
1,100
|
-
|
|
-
|
Emerging Markets
|
3,370
|
3
|
983
|
9
|
|
-
|
Japan
|
1,058
|
6
|
316
|
26
|
|
-
|
ViiV Healthcare
|
1,386
|
-
|
385
|
15
|
|
-
|
Established Products
|
3,874
|
(8)
|
947
|
(9)
|
|
-
|
Other trading and unallocated pharmaceuticals
|
1,115
|
11
|
328
|
26
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Pharmaceuticals and Vaccines
|
20,846
|
1
|
5,573
|
6
|
|
|
Consumer Healthcare
|
4,756
|
2
|
1,127
|
-
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Segment turnover excluding divestments
|
25,602
|
2
|
6,700
|
5
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Segment turnover including divestments
|
26,505
|
1
|
6,906
|
5
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
9 months 2013
|
Q3 2013
|
||||
|
-----------------------------------
|
-----------------------------------
|
||||
|
£m
|
Growth
CER%
|
£m
|
Growth
CER%
|
||
|
------------
|
------------
|
------------
|
------------
|
||
|
Pharmaceuticals and Vaccines
|
|||||
|
-
|
US
|
4,303
|
2
|
1,522
|
4
|
|
-
|
Europe
|
3,126
|
4
|
1,049
|
9
|
|
-
|
Emerging Markets
|
2,387
|
1
|
781
|
(7)
|
|
-
|
Japan
|
742
|
(1)
|
210
|
3
|
|
-
|
ViiV Healthcare
|
1,001
|
(5)
|
344
|
(5)
|
|
-
|
Established Products
|
2,927
|
(8)
|
906
|
(9)
|
|
-
|
Other trading and unallocated pharmaceuticals
|
787
|
6
|
272
|
10
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Pharmaceuticals and Vaccines
|
15,273
|
-
|
5,084
|
-
|
|
|
Consumer Healthcare
|
3,629
|
3
|
1,190
|
4
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Segment turnover excluding divestments
|
18,902
|
-
|
6,274
|
1
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Segment turnover including divestments
|
19,599
|
-
|
6,510
|
1
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
6 months 2013
|
Q2 2013
|
||||
|
-----------------------------------
|
-----------------------------------
|
||||
|
£m
|
Growth
CER%
|
£m
|
Growth
CER%
|
||
|
------------
|
------------
|
------------
|
------------
|
||
|
Pharmaceuticals and Vaccines
|
|||||
|
-
|
US
|
2,781
|
1
|
1,439
|
11
|
|
-
|
Europe
|
2,077
|
2
|
1,060
|
4
|
|
-
|
Emerging Markets
|
1,606
|
6
|
840
|
3
|
|
-
|
Japan
|
532
|
(3)
|
229
|
3
|
|
-
|
ViiV Healthcare
|
657
|
(5)
|
339
|
(4)
|
|
-
|
Established Products
|
2,021
|
(8)
|
1,018
|
(10)
|
|
-
|
Other trading and unallocated pharmaceuticals
|
515
|
4
|
260
|
4
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Pharmaceuticals and Vaccines
|
10,189
|
-
|
5,185
|
2
|
|
|
Consumer Healthcare
|
2,439
|
2
|
1,188
|
2
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Segment turnover excluding divestments
|
12,628
|
-
|
6,373
|
2
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Segment turnover including divestments
|
13,089
|
-
|
6,618
|
2
|
|
|
------------
|
------------
|
------------
|
------------
|
||
|
Q1 2013
|
|||||
|
-----------------------------------
|
|||||
|
£m
|
Growth
CER%
|
||||
|
------------
|
------------
|
||||
|
Pharmaceuticals and Vaccines
|
|||||
|
-
|
US
|
1,342
|
(7)
|
||
|
-
|
Europe
|
1,017
|
1
|
||
|
-
|
Emerging Markets
|
766
|
9
|
||
|
-
|
Japan
|
303
|
(7)
|
||
|
-
|
ViiV Healthcare
|
318
|
(5)
|
||
|
-
|
Established Products
|
1,003
|
(5)
|
||
|
-
|
Other trading and unallocated pharmaceuticals
|
255
|
3
|
||
|
------------
|
------------
|
||||
|
Pharmaceuticals and Vaccines
|
5,004
|
(2)
|
|||
|
Consumer Healthcare
|
1,251
|
1
|
|||
|
------------
|
------------
|
||||
|
Segment turnover excluding divestments
|
6,255
|
(2)
|
|||
|
------------
|
------------
|
||||
|
Segment turnover including divestments
|
6,471
|
(2)
|
|||
|
------------
|
------------
|
||||
|
2012
|
|||||
|
-----------------------------------
|
|||||
|
£m
|
|||||
|
------------
|
|||||
|
Pharmaceuticals and Vaccines
|
|||||
|
-
|
US
|
5,508
|
|||
|
-
|
Europe
|
3,956
|
|||
|
-
|
Emerging Markets
|
3,309
|
|||
|
-
|
Japan
|
1,203
|
|||
|
-
|
ViiV Healthcare
|
1,374
|
|||
|
-
|
Established Products
|
4,351
|
|||
|
-
|
Other trading and unallocated pharmaceuticals
|
1,035
|
|||
|
------------
|
|||||
|
Pharmaceuticals and Vaccines
|
20,736
|
||||
|
Consumer Healthcare
|
4,747
|
||||
|
------------
|
|||||
|
Segment turnover excluding 2013 divestments
|
25,483
|
||||
|
------------
|
|||||
|
Segment turnover including 2013 divestments
|
26,431
|
||||
|
------------
|
|||||
|
Pharmaceuticals and Vaccines turnover
|
||||||||||
|
Twelve months ended 31 December 2013
|
||||||||||
|
Total
|
USA
|
Europe
|
Emerging Markets
|
Japan
|
||||||
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
||||||
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Respiratory
|
7,289
|
4
|
3,594
|
7
|
1,802
|
(2)
|
837
|
4
|
554
|
10
|
|
Avamys/Veramyst
|
249
|
5
|
42
|
(29)
|
69
|
8
|
71
|
16
|
49
|
28
|
|
Flixotide/Flovent
|
796
|
2
|
482
|
6
|
117
|
(7)
|
58
|
7
|
42
|
(7)
|
|
Relvar/Breo
|
8
|
-
|
5
|
-
|
-
|
-
|
-
|
-
|
3
|
-
|
|
Seretide/Advair
|
5,274
|
4
|
2,769
|
8
|
1,458
|
(2)
|
429
|
4
|
277
|
8
|
|
Ventolin
|
642
|
2
|
291
|
4
|
127
|
(2)
|
171
|
2
|
9
|
-
|
|
Other
|
320
|
4
|
5
|
(69)
|
31
|
(6)
|
108
|
(1)
|
174
|
14
|
|
Oncology
|
969
|
22
|
380
|
17
|
339
|
28
|
149
|
18
|
63
|
36
|
|
Arzerra
|
75
|
23
|
46
|
18
|
27
|
29
|
-
|
-
|
1
|
-
|
|
Mekinist
|
10
|
-
|
10
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Promacta
|
186
|
46
|
73
|
33
|
55
|
47
|
22
|
92
|
30
|
44
|
|
Tafinlar
|
16
|
-
|
11
|
-
|
4
|
-
|
-
|
-
|
-
|
-
|
|
Tyverb/Tykerb
|
207
|
(13)
|
55
|
(21)
|
82
|
(9)
|
47
|
(9)
|
17
|
(5)
|
|
Votrient
|
331
|
80
|
144
|
56
|
130
|
91
|
37
|
77
|
9
|
>100
|
|
Other
|
144
|
(23)
|
41
|
(40)
|
41
|
(17)
|
43
|
2
|
6
|
(25)
|
|
Cardiovascular, metabolic and urology (CVMU)
|
1,073
|
(5)
|
456
|
(27)
|
308
|
18
|
135
|
27
|
114
|
25
|
|
Avodart
|
857
|
10
|
312
|
(3)
|
273
|
15
|
104
|
27
|
114
|
25
|
|
Other
|
216
|
(40)
|
144
|
(53)
|
35
|
48
|
31
|
24
|
-
|
-
|
|
Immuno-inflammation
|
161
|
>100
|
148
|
>100
|
8
|
100
|
1
|
-
|
-
|
-
|
|
Benlysta
|
146
|
>100
|
134
|
>100
|
8
|
100
|
1
|
-
|
-
|
-
|
|
Other
|
15
|
-
|
14
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
2,674
|
5
|
261
|
(25)
|
720
|
2
|
1,124
|
2
|
291
|
36
|
|
Dermatology
|
631
|
(5)
|
115
|
(37)
|
170
|
6
|
289
|
8
|
28
|
3
|
|
Augmentin
|
630
|
5
|
1
|
-
|
203
|
(3)
|
393
|
11
|
13
|
(6)
|
|
Other anti-bacterials
|
224
|
(4)
|
7
|
-
|
66
|
5
|
148
|
(4)
|
3
|
-
|
|
Rare diseases
|
495
|
7
|
113
|
(4)
|
129
|
1
|
48
|
2
|
184
|
18
|
|
Other
|
694
|
18
|
25
|
(37)
|
152
|
6
|
246
|
(11)
|
63
|
>100
|
|
Vaccines
|
3,420
|
2
|
978
|
17
|
1,049
|
3
|
1,124
|
1
|
36
|
(76)
|
|
Boostrix
|
288
|
19
|
183
|
23
|
65
|
19
|
20
|
25
|
-
|
-
|
|
Cervarix
|
172
|
(37)
|
6
|
-
|
61
|
11
|
92
|
23
|
10
|
(90)
|
|
Fluarix, FluLaval
|
251
|
25
|
146
|
65
|
35
|
(21)
|
43
|
(2)
|
-
|
-
|
|
Hepatitis
|
629
|
(4)
|
263
|
(3)
|
198
|
(3)
|
123
|
(2)
|
-
|
-
|
|
Infanrix, Pediarix
|
862
|
9
|
271
|
23
|
398
|
2
|
132
|
11
|
-
|
-
|
|
Rotarix
|
375
|
5
|
108
|
7
|
59
|
49
|
164
|
3
|
25
|
(30)
|
|
Synflorix
|
405
|
2
|
-
|
-
|
48
|
2
|
350
|
1
|
-
|
-
|
|
Other
|
438
|
(4)
|
1
|
(100)
|
185
|
2
|
200
|
(14)
|
1
|
-
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Innovative products
|
15,586
|
4
|
5,817
|
4
|
4,226
|
3
|
3,370
|
3
|
1,058
|
6
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|||
|
ViiV Healthcare (HIV)
|
1,386
|
-
|
552
|
5
|
526
|
(3)
|
171
|
(12)
|
54
|
14
|
|
Combivir
|
116
|
(36)
|
35
|
46
|
39
|
(41)
|
35
|
(56)
|
3
|
(11)
|
|
Epzicom/Kivexa
|
763
|
14
|
269
|
9
|
328
|
11
|
78
|
38
|
36
|
21
|
|
Lexiva/Agenerase
|
113
|
(11)
|
62
|
(10)
|
27
|
(22)
|
18
|
(1)
|
3
|
(7)
|
|
Selzentry
|
143
|
10
|
58
|
1
|
63
|
8
|
6
|
67
|
3
|
49
|
|
Tivicay
|
19
|
-
|
19
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Trizivir
|
97
|
(10)
|
58
|
(6)
|
32
|
(17)
|
4
|
(26)
|
-
|
-
|
|
Other
|
135
|
(20)
|
51
|
(25)
|
37
|
(26)
|
30
|
(8)
|
9
|
(5)
|
|
Established products
|
3,874
|
(8)
|
1,300
|
(7)
|
718
|
(14)
|
1,157
|
(5)
|
595
|
(5)
|
|
Coreg
|
131
|
(2)
|
130
|
(2)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Hepsera
|
96
|
(21)
|
-
|
-
|
-
|
-
|
70
|
(28)
|
25
|
(3)
|
|
Imigran/Imitrex
|
188
|
1
|
80
|
11
|
63
|
(7)
|
7
|
-
|
24
|
(13)
|
|
Lamictal
|
557
|
(7)
|
276
|
(18)
|
110
|
(4)
|
78
|
8
|
83
|
28
|
|
Lovaza
|
584
|
(5)
|
581
|
(5)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Requip
|
125
|
(18)
|
7
|
(63)
|
52
|
(33)
|
14
|
-
|
51
|
11
|
|
Serevent
|
129
|
(10)
|
51
|
(2)
|
55
|
(17)
|
4
|
33
|
13
|
(20)
|
|
Seroxat/Paxil
|
285
|
(16)
|
-
|
-
|
53
|
(11)
|
79
|
(4)
|
138
|
(22)
|
|
Valtrex
|
224
|
(2)
|
45
|
26
|
29
|
(15)
|
40
|
11
|
106
|
(2)
|
|
Zeffix
|
182
|
(26)
|
13
|
(13)
|
12
|
(25)
|
140
|
(28)
|
16
|
(5)
|
|
Other
|
1,373
|
(6)
|
117
|
(5)
|
344
|
(14)
|
725
|
2
|
139
|
(5)
|
|
----------
|
----------
|
|||||||||
|
20,846
|
1
|
|||||||||
|
----------
|
----------
|
|||||||||
|
Total
|
USA
|
Europe
|
Emerging Markets
|
Japan
|
||||||
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
||||||
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Respiratory
|
1,923
|
7
|
958
|
14
|
454
|
(4)
|
227
|
4
|
152
|
13
|
|
Avamys/Veramyst
|
54
|
(5)
|
6
|
(56)
|
16
|
23
|
18
|
6
|
9
|
38
|
|
Flixotide/Flovent
|
209
|
4
|
124
|
8
|
30
|
(9)
|
17
|
13
|
12
|
-
|
|
Relvar/Breo
|
8
|
-
|
5
|
-
|
-
|
-
|
-
|
-
|
3
|
-
|
|
Seretide/Advair
|
1,398
|
9
|
741
|
17
|
368
|
(4)
|
119
|
6
|
82
|
11
|
|
Ventolin
|
175
|
1
|
80
|
3
|
33
|
(6)
|
47
|
6
|
3
|
-
|
|
Other
|
79
|
(1)
|
2
|
(47)
|
7
|
(25)
|
26
|
(10)
|
43
|
10
|
|
Oncology
|
266
|
24
|
102
|
21
|
89
|
26
|
46
|
22
|
16
|
31
|
|
Arzerra
|
19
|
36
|
13
|
30
|
5
|
25
|
-
|
-
|
-
|
-
|
|
Mekinist
|
7
|
-
|
7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Promacta
|
52
|
42
|
19
|
27
|
16
|
45
|
6
|
75
|
8
|
43
|
|
Tafinlar
|
11
|
-
|
6
|
-
|
4
|
-
|
-
|
-
|
-
|
-
|
|
Tyverb/Tykerb
|
49
|
(18)
|
11
|
(35)
|
19
|
(10)
|
14
|
-
|
4
|
-
|
|
Votrient
|
90
|
48
|
39
|
34
|
35
|
55
|
11
|
33
|
2
|
>100
|
|
Other
|
38
|
(12)
|
7
|
(37)
|
10
|
(19)
|
15
|
23
|
2
|
(33)
|
|
Cardiovascular, metabolic and urology (CVMU)
|
283
|
14
|
116
|
4
|
81
|
13
|
36
|
39
|
33
|
25
|
|
Avodart
|
226
|
13
|
80
|
1
|
72
|
13
|
27
|
43
|
33
|
25
|
|
Other
|
57
|
19
|
36
|
10
|
9
|
13
|
9
|
29
|
-
|
-
|
|
Immuno-inflammation
|
46
|
59
|
41
|
57
|
2
|
50
|
-
|
-
|
-
|
-
|
|
Benlysta
|
37
|
28
|
33
|
26
|
2
|
50
|
-
|
-
|
-
|
-
|
|
Other
|
9
|
-
|
8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
756
|
7
|
54
|
(49)
|
199
|
(3)
|
285
|
(3)
|
107
|
72
|
|
Dermatology
|
135
|
(17)
|
13
|
(71)
|
42
|
(2)
|
67
|
3
|
7
|
13
|
|
Augmentin
|
165
|
3
|
1
|
-
|
53
|
(4)
|
101
|
6
|
4
|
-
|
|
Other anti-bacterials
|
57
|
(11)
|
2
|
-
|
18
|
6
|
36
|
(11)
|
1
|
-
|
|
Rare diseases
|
130
|
(1)
|
27
|
(24)
|
34
|
3
|
14
|
(7)
|
49
|
11
|
|
Other
|
269
|
43
|
11
|
(53)
|
52
|
(10)
|
67
|
(15)
|
46
|
>100
|
|
Vaccines
|
967
|
12
|
243
|
23
|
275
|
-
|
389
|
22
|
8
|
(44)
|
|
Boostrix
|
91
|
65
|
65
|
97
|
15
|
7
|
7
|
40
|
-
|
-
|
|
Cervarix
|
45
|
2
|
1
|
-
|
19
|
38
|
25
|
18
|
(1)
|
-
|
|
Fluarix, FluLaval
|
87
|
76
|
36
|
>100
|
21
|
(23)
|
22
|
>100
|
-
|
-
|
|
Hepatitis
|
152
|
(4)
|
55
|
(7)
|
52
|
2
|
34
|
12
|
-
|
-
|
|
Infanrix, Pediarix
|
208
|
(11)
|
61
|
(10)
|
101
|
(4)
|
32
|
(33)
|
-
|
-
|
|
Rotarix
|
100
|
17
|
24
|
(4)
|
15
|
50
|
46
|
31
|
8
|
-
|
|
Synflorix
|
161
|
49
|
-
|
-
|
12
|
(8)
|
147
|
58
|
-
|
-
|
|
Other
|
123
|
(3)
|
1
|
<(100)
|
40
|
-
|
76
|
1
|
1
|
-
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Innovative products
|
4,241
|
10
|
1,514
|
11
|
1,100
|
-
|
983
|
9
|
316
|
26
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|||
|
ViiV Healthcare (HIV)
|
385
|
15
|
171
|
30
|
135
|
1
|
41
|
7
|
15
|
13
|
|
Combivir
|
31
|
(26)
|
11
|
27
|
7
|
(52)
|
11
|
(32)
|
-
|
(11)
|
|
Epzicom/Kivexa
|
211
|
28
|
80
|
35
|
88
|
15
|
18
|
70
|
10
|
18
|
|
Lexiva/Agenerase
|
28
|
(9)
|
18
|
2
|
6
|
(23)
|
3
|
(38)
|
-
|
(5)
|
|
Selzentry
|
37
|
(3)
|
14
|
(16)
|
17
|
11
|
1
|
(4)
|
-
|
28
|
|
Tivicay
|
15
|
-
|
15
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Trizivir
|
26
|
-
|
16
|
2
|
7
|
(11)
|
1
|
>100
|
-
|
-
|
|
Other
|
37
|
12
|
17
|
32
|
10
|
(11)
|
7
|
33
|
5
|
2
|
|
Established products
|
947
|
(9)
|
321
|
(10)
|
176
|
(11)
|
275
|
(7)
|
150
|
1
|
|
Coreg
|
29
|
(3)
|
29
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Hepsera
|
23
|
(27)
|
-
|
-
|
-
|
-
|
15
|
(36)
|
6
|
-
|
|
Imigran/Imitrex
|
46
|
-
|
18
|
6
|
15
|
(6)
|
2
|
-
|
6
|
(13)
|
|
Lamictal
|
152
|
(3)
|
77
|
(15)
|
28
|
-
|
20
|
16
|
23
|
26
|
|
Lovaza
|
140
|
(5)
|
139
|
(5)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Requip
|
29
|
(3)
|
1
|
-
|
11
|
(29)
|
3
|
-
|
14
|
13
|
|
Serevent
|
31
|
(9)
|
13
|
(8)
|
14
|
(13)
|
1
|
-
|
3
|
(20)
|
|
Seroxat/Paxil
|
69
|
(14)
|
-
|
-
|
12
|
(27)
|
19
|
(9)
|
35
|
(9)
|
|
Valtrex
|
59
|
(7)
|
15
|
(30)
|
7
|
17
|
10
|
22
|
26
|
-
|
|
Zeffix
|
43
|
(30)
|
3
|
(40)
|
3
|
-
|
33
|
(31)
|
4
|
-
|
|
Other
|
326
|
(10)
|
26
|
(18)
|
86
|
(11)
|
172
|
(1)
|
33
|
2
|
|
----------
|
----------
|
|||||||||
|
5,573
|
6
|
|||||||||
|
----------
|
----------
|
|||||||||
|
Total
|
USA
|
Europe
|
Emerging Markets
|
Japan
|
||||||
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
||||||
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Respiratory
|
1,640
|
(2)
|
816
|
(3)
|
418
|
(1)
|
182
|
(6)
|
105
|
6
|
|
Avamys/Veramyst
|
55
|
8
|
13
|
(14)
|
13
|
8
|
20
|
31
|
5
|
(13)
|
|
Flixotide/Flovent
|
172
|
(7)
|
105
|
(8)
|
25
|
(4)
|
12
|
-
|
9
|
(8)
|
|
Relvar/Breo
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Seretide/Advair
|
1,209
|
(1)
|
632
|
(1)
|
344
|
(1)
|
87
|
(12)
|
62
|
8
|
|
Ventolin
|
145
|
(5)
|
66
|
(10)
|
29
|
-
|
39
|
3
|
2
|
50
|
|
Other
|
59
|
(2)
|
-
|
-
|
7
|
-
|
24
|
(18)
|
27
|
9
|
|
Oncology
|
249
|
23
|
99
|
14
|
91
|
32
|
36
|
19
|
16
|
36
|
|
Arzerra
|
18
|
(11)
|
13
|
20
|
4
|
(50)
|
-
|
-
|
1
|
-
|
|
Mekinist
|
3
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Promacta
|
49
|
43
|
19
|
27
|
15
|
56
|
6
|
100
|
8
|
43
|
|
Tafinlar
|
4
|
-
|
4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Tyverb/Tykerb
|
53
|
(7)
|
14
|
(18)
|
21
|
(10)
|
12
|
8
|
4
|
(17)
|
|
Votrient
|
91
|
84
|
36
|
38
|
39
|
>100
|
10
|
100
|
3
|
-
|
|
Other
|
31
|
(26)
|
10
|
(51)
|
12
|
10
|
8
|
(27)
|
-
|
-
|
|
Cardiovascular, metabolic and urology (CVMU)
|
262
|
7
|
110
|
(6)
|
76
|
20
|
33
|
14
|
28
|
30
|
|
Avodart
|
207
|
6
|
73
|
(11)
|
67
|
17
|
26
|
13
|
28
|
30
|
|
Other
|
55
|
11
|
37
|
6
|
9
|
60
|
7
|
17
|
-
|
-
|
|
Immuno-inflammation
|
48
|
>100
|
45
|
>100
|
2
|
100
|
1
|
-
|
-
|
-
|
|
Benlysta
|
42
|
>100
|
39
|
100
|
2
|
100
|
1
|
-
|
-
|
-
|
|
Other
|
6
|
-
|
6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
648
|
4
|
77
|
(20)
|
189
|
31
|
266
|
(7)
|
55
|
11
|
|
Dermatology
|
165
|
2
|
39
|
(1)
|
42
|
5
|
70
|
4
|
6
|
-
|
|
Augmentin
|
140
|
1
|
-
|
-
|
43
|
5
|
90
|
1
|
3
|
-
|
|
Other anti-bacterials
|
46
|
(12)
|
2
|
70
|
13
|
6
|
32
|
(19)
|
1
|
-
|
|
Rare diseases
|
125
|
(1)
|
30
|
(26)
|
32
|
7
|
13
|
-
|
45
|
14
|
|
Other
|
172
|
21
|
6
|
(56)
|
59
|
>100
|
61
|
(17)
|
-
|
-
|
|
Vaccines
|
987
|
3
|
375
|
24
|
273
|
4
|
263
|
(14)
|
6
|
(75)
|
|
Boostrix
|
83
|
4
|
56
|
(2)
|
18
|
21
|
4
|
33
|
-
|
-
|
|
Cervarix
|
41
|
(11)
|
2
|
(33)
|
14
|
27
|
25
|
32
|
-
|
-
|
|
Fluarix, FluLaval
|
142
|
1
|
104
|
29
|
16
|
(16)
|
7
|
(69)
|
-
|
-
|
|
Hepatitis
|
168
|
(1)
|
81
|
5
|
48
|
(4)
|
29
|
(15)
|
-
|
-
|
|
Infanrix, Pediarix
|
258
|
26
|
100
|
69
|
98
|
1
|
44
|
26
|
-
|
-
|
|
Rotarix
|
108
|
5
|
32
|
19
|
17
|
78
|
50
|
2
|
6
|
(56)
|
|
Synflorix
|
80
|
(28)
|
-
|
-
|
12
|
(8)
|
66
|
(32)
|
-
|
-
|
|
Other
|
107
|
4
|
-
|
-
|
50
|
2
|
38
|
(12)
|
-
|
-
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Innovative products
|
3,834
|
3
|
1,522
|
4
|
1,049
|
9
|
781
|
(7)
|
210
|
3
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|||
|
ViiV Healthcare (HIV)
|
344
|
(5)
|
136
|
3
|
124
|
(7)
|
51
|
(26)
|
13
|
13
|
|
Combivir
|
25
|
(55)
|
7
|
11
|
8
|
(50)
|
8
|
(73)
|
1
|
(10)
|
|
Epzicom/Kivexa
|
190
|
8
|
65
|
(3)
|
79
|
8
|
24
|
20
|
9
|
22
|
|
Lexiva/Agenerase
|
29
|
(6)
|
15
|
(4)
|
6
|
(22)
|
7
|
8
|
1
|
(7)
|
|
Selzentry
|
34
|
10
|
16
|
16
|
14
|
2
|
1
|
89
|
1
|
36
|
|
Tivicay
|
4
|
-
|
4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Trizivir
|
24
|
(4)
|
15
|
(1)
|
8
|
(19)
|
2
|
(4)
|
-
|
-
|
|
Other
|
38
|
(13)
|
14
|
-
|
9
|
(37)
|
9
|
(7)
|
1
|
(8)
|
|
Established products
|
906
|
(9)
|
320
|
(3)
|
172
|
(14)
|
245
|
(18)
|
149
|
1
|
|
Coreg
|
36
|
9
|
36
|
9
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Hepsera
|
15
|
(47)
|
-
|
-
|
-
|
-
|
10
|
(63)
|
6
|
(13)
|
|
Imigran/Imitrex
|
47
|
2
|
21
|
18
|
15
|
(6)
|
1
|
-
|
6
|
(22)
|
|
Lamictal
|
139
|
(6)
|
70
|
(16)
|
27
|
(4)
|
19
|
-
|
21
|
30
|
|
Lovaza
|
135
|
(12)
|
134
|
(12)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Requip
|
36
|
(5)
|
3
|
-
|
13
|
(37)
|
4
|
-
|
15
|
29
|
|
Serevent
|
32
|
(6)
|
13
|
8
|
13
|
(25)
|
1
|
-
|
3
|
(20)
|
|
Seroxat/Paxil
|
64
|
(9)
|
-
|
-
|
12
|
(8)
|
16
|
(16)
|
34
|
(5)
|
|
Valtrex
|
55
|
17
|
10
|
-
|
8
|
-
|
11
|
-
|
26
|
-
|
|
Zeffix
|
27
|
(57)
|
3
|
(25)
|
3
|
(25)
|
16
|
(69)
|
4
|
-
|
|
Other
|
320
|
(5)
|
30
|
22
|
81
|
(13)
|
167
|
(3)
|
34
|
(7)
|
|
----------
|
----------
|
|||||||||
|
5,084
|
-
|
|||||||||
|
----------
|
----------
|
|||||||||
|
Total
|
USA
|
Europe
|
Emerging Markets
|
Japan
|
||||||
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
||||||
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Respiratory
|
1,847
|
4
|
914
|
8
|
469
|
(1)
|
224
|
10
|
113
|
(4)
|
|
Avamys/Veramyst
|
60
|
(6)
|
12
|
(20)
|
23
|
5
|
17
|
6
|
3
|
(38)
|
|
Flixotide/Flovent
|
202
|
5
|
124
|
12
|
29
|
(13)
|
14
|
-
|
11
|
(13)
|
|
Relvar/Breo
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Seretide/Advair
|
1,358
|
5
|
708
|
8
|
376
|
(1)
|
117
|
14
|
70
|
8
|
|
Ventolin
|
160
|
7
|
69
|
18
|
32
|
-
|
44
|
-
|
2
|
-
|
|
Other
|
67
|
(9)
|
1
|
(54)
|
9
|
-
|
32
|
19
|
27
|
(17)
|
|
Oncology
|
233
|
17
|
91
|
10
|
80
|
26
|
36
|
23
|
17
|
43
|
|
Arzerra
|
17
|
20
|
10
|
22
|
7
|
17
|
-
|
-
|
-
|
-
|
|
Mekinist
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Promacta
|
45
|
53
|
19
|
38
|
13
|
50
|
5
|
67
|
8
|
50
|
|
Tafinlar
|
1
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Tyverb/Tykerb
|
53
|
(12)
|
15
|
(18)
|
21
|
(5)
|
11
|
(21)
|
5
|
-
|
|
Votrient
|
79
|
97
|
36
|
70
|
30
|
100
|
9
|
>100
|
2
|
-
|
|
Other
|
38
|
(33)
|
10
|
(50)
|
9
|
(18)
|
11
|
22
|
2
|
-
|
|
Cardiovascular, metabolic and urology (CVMU)
|
275
|
15
|
122
|
6
|
78
|
16
|
35
|
30
|
28
|
21
|
|
Avodart
|
221
|
12
|
84
|
1
|
68
|
10
|
27
|
35
|
28
|
21
|
|
Other
|
54
|
30
|
38
|
19
|
10
|
67
|
8
|
14
|
-
|
-
|
|
Immuno-inflammation
|
38
|
>100
|
35
|
>100
|
2
|
-
|
-
|
-
|
-
|
-
|
|
Benlysta
|
38
|
>100
|
35
|
>100
|
2
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
649
|
8
|
63
|
-
|
167
|
4
|
298
|
11
|
60
|
23
|
|
Dermatology
|
169
|
1
|
31
|
(35)
|
44
|
14
|
79
|
18
|
8
|
-
|
|
Augmentin
|
150
|
-
|
-
|
-
|
45
|
(13)
|
99
|
11
|
3
|
(25)
|
|
Other anti-bacterials
|
60
|
6
|
2
|
41
|
14
|
6
|
42
|
9
|
-
|
-
|
|
Rare diseases
|
127
|
21
|
29
|
53
|
32
|
(3)
|
12
|
20
|
48
|
27
|
|
Other
|
143
|
15
|
1
|
(74)
|
32
|
29
|
66
|
2
|
1
|
-
|
|
Vaccines
|
786
|
-
|
214
|
14
|
264
|
5
|
247
|
(13)
|
11
|
(43)
|
|
Boostrix
|
68
|
16
|
41
|
8
|
19
|
38
|
5
|
67
|
-
|
-
|
|
Cervarix
|
46
|
(8)
|
2
|
100
|
13
|
(20)
|
25
|
19
|
4
|
(54)
|
|
Fluarix, FluLaval
|
7
|
40
|
2
|
100
|
(1)
|
50
|
5
|
-
|
-
|
-
|
|
Hepatitis
|
170
|
1
|
73
|
3
|
52
|
(4)
|
36
|
(3)
|
-
|
-
|
|
Infanrix, Pediarix
|
218
|
18
|
72
|
31
|
103
|
8
|
28
|
27
|
-
|
-
|
|
Rotarix
|
87
|
(8)
|
25
|
9
|
16
|
60
|
37
|
(23)
|
6
|
(20)
|
|
Synflorix
|
74
|
(31)
|
-
|
-
|
12
|
-
|
60
|
(37)
|
-
|
-
|
|
Other
|
116
|
(2)
|
(1)
|
-
|
50
|
(2)
|
51
|
(7)
|
1
|
-
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Innovative products
|
3,828
|
6
|
1,439
|
11
|
1,060
|
4
|
840
|
3
|
229
|
3
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|||
|
ViiV Healthcare (HIV)
|
339
|
(4)
|
119
|
(4)
|
136
|
(1)
|
50
|
(17)
|
14
|
11
|
|
Combivir
|
27
|
(45)
|
6
|
19
|
10
|
(43)
|
9
|
(60)
|
1
|
(14)
|
|
Epzicom/Kivexa
|
193
|
13
|
63
|
6
|
84
|
14
|
23
|
35
|
9
|
21
|
|
Lexiva/Agenerase
|
29
|
(12)
|
14
|
(25)
|
7
|
(19)
|
6
|
63
|
1
|
(17)
|
|
Selzentry
|
35
|
10
|
15
|
5
|
17
|
10
|
2
|
1
|
1
|
51
|
|
Tivicay
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Trizivir
|
23
|
(24)
|
13
|
(16)
|
8
|
(22)
|
1
|
-
|
-
|
-
|
|
Other
|
32
|
(18)
|
8
|
(26)
|
10
|
(6)
|
9
|
(22)
|
2
|
(11)
|
|
Established products
|
1,018
|
(10)
|
331
|
(11)
|
175
|
(16)
|
321
|
1
|
153
|
(14)
|
|
Coreg
|
33
|
(6)
|
33
|
(9)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Hepsera
|
31
|
(3)
|
-
|
-
|
-
|
-
|
24
|
(8)
|
7
|
-
|
|
Imigran/Imitrex
|
47
|
(8)
|
19
|
(14)
|
16
|
(11)
|
2
|
(50)
|
6
|
-
|
|
Lamictal
|
133
|
(8)
|
63
|
(18)
|
27
|
(10)
|
20
|
5
|
21
|
25
|
|
Lovaza
|
161
|
-
|
161
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Requip
|
29
|
(30)
|
1
|
(83)
|
13
|
(37)
|
3
|
(25)
|
12
|
7
|
|
Serevent
|
33
|
(13)
|
12
|
-
|
14
|
(13)
|
1
|
-
|
4
|
(20)
|
|
Seroxat/Paxil
|
79
|
(24)
|
-
|
-
|
15
|
(7)
|
21
|
-
|
37
|
(37)
|
|
Valtrex
|
55
|
(9)
|
9
|
-
|
7
|
(30)
|
10
|
11
|
28
|
-
|
|
Zeffix
|
55
|
(12)
|
4
|
-
|
3
|
(25)
|
44
|
(11)
|
4
|
(17)
|
|
Other
|
362
|
(9)
|
29
|
(37)
|
80
|
(15)
|
196
|
5
|
34
|
(17)
|
|
----------
|
----------
|
|||||||||
|
5,185
|
2
|
|||||||||
|
----------
|
----------
|
|||||||||
|
Total
|
USA
|
Europe
|
Emerging Markets
|
Japan
|
||||||
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
----------------------------
|
||||||
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
£m
|
CER%
|
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Respiratory
|
1,879
|
6
|
906
|
7
|
461
|
(2)
|
204
|
8
|
184
|
24
|
|
Avamys/Veramyst
|
80
|
22
|
11
|
(21)
|
17
|
-
|
16
|
23
|
32
|
64
|
|
Flixotide/Flovent
|
213
|
7
|
129
|
13
|
33
|
(3)
|
15
|
15
|
10
|
(8)
|
|
Relvar/Breo
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Seretide/Advair
|
1,309
|
4
|
688
|
8
|
370
|
(2)
|
106
|
8
|
63
|
4
|
|
Ventolin
|
162
|
4
|
76
|
9
|
33
|
-
|
41
|
-
|
2
|
(33)
|
|
Other
|
115
|
24
|
2
|
(71)
|
8
|
-
|
26
|
8
|
77
|
40
|
|
Oncology
|
221
|
23
|
88
|
24
|
79
|
26
|
31
|
7
|
14
|
33
|
|
Arzerra
|
21
|
67
|
10
|
-
|
11
|
>100
|
-
|
-
|
-
|
-
|
|
Mekinist
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Promacta
|
40
|
48
|
16
|
45
|
11
|
38
|
5
|
>100
|
6
|
40
|
|
Tafinlar
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Tyverb/Tykerb
|
52
|
(13)
|
15
|
(12)
|
21
|
(13)
|
10
|
(23)
|
4
|
-
|
|
Votrient
|
71
|
>100
|
33
|
>100
|
26
|
100
|
7
|
75
|
2
|
-
|
|
Other
|
37
|
(19)
|
14
|
(18)
|
10
|
(33)
|
9
|
(10)
|
2
|
-
|
|
Cardiovascular, metabolic and urology (CVMU)
|
253
|
(37)
|
108
|
(62)
|
73
|
24
|
31
|
24
|
25
|
22
|
|
Avodart
|
203
|
10
|
75
|
(3)
|
66
|
20
|
24
|
20
|
25
|
22
|
|
Other
|
50
|
(78)
|
33
|
(84)
|
7
|
75
|
7
|
40
|
-
|
-
|
|
Immuno-inflammation
|
29
|
>100
|
27
|
>100
|
2
|
100
|
-
|
-
|
-
|
-
|
|
Benlysta
|
29
|
>100
|
27
|
>100
|
2
|
100
|
-
|
-
|
-
|
-
|
|
Other
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
621
|
-
|
67
|
(20)
|
165
|
(14)
|
275
|
9
|
69
|
29
|
|
Dermatology
|
162
|
(6)
|
32
|
(37)
|
42
|
11
|
73
|
7
|
7
|
-
|
|
Augmentin
|
175
|
16
|
-
|
-
|
62
|
-
|
103
|
27
|
3
|
-
|
|
Other anti-bacterials
|
61
|
3
|
1
|
(58)
|
21
|
3
|
38
|
5
|
1
|
23
|
|
Rare diseases
|
113
|
12
|
27
|
18
|
31
|
(3)
|
9
|
-
|
42
|
23
|
|
Other
|
110
|
(18)
|
7
|
(13)
|
9
|
(77)
|
52
|
(9)
|
16
|
86
|
|
Vaccines
|
680
|
(11)
|
146
|
(3)
|
237
|
4
|
225
|
7
|
11
|
(88)
|
|
Boostrix
|
46
|
(4)
|
21
|
-
|
13
|
8
|
4
|
(20)
|
-
|
-
|
|
Cervarix
|
40
|
(69)
|
1
|
-
|
15
|
7
|
17
|
23
|
7
|
(93)
|
|
Fluarix, FluLaval
|
15
|
>100
|
4
|
-
|
(1)
|
-
|
9
|
>100
|
-
|
-
|
|
Hepatitis
|
139
|
(10)
|
54
|
(14)
|
46
|
(4)
|
24
|
(4)
|
-
|
-
|
|
Infanrix, Pediarix
|
178
|
10
|
38
|
-
|
96
|
3
|
28
|
100
|
-
|
-
|
|
Rotarix
|
80
|
7
|
27
|
4
|
11
|
10
|
31
|
14
|
5
|
(29)
|
|
Synflorix
|
90
|
23
|
-
|
-
|
12
|
33
|
77
|
26
|
-
|
-
|
|
Other
|
92
|
(15)
|
1
|
-
|
45
|
8
|
35
|
(42)
|
(1)
|
-
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|
|
Innovative products
|
3,683
|
(1)
|
1,342
|
(7)
|
1,017
|
1
|
766
|
9
|
303
|
(7)
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
----------
|
|||
|
ViiV Healthcare (HIV)
|
318
|
(5)
|
126
|
(10)
|
131
|
(6)
|
29
|
2
|
12
|
19
|
|
Combivir
|
33
|
(6)
|
11
|
>100
|
14
|
(23)
|
7
|
(32)
|
1
|
(7)
|
|
Epzicom/Kivexa
|
169
|
6
|
61
|
-
|
77
|
6
|
13
|
46
|
8
|
25
|
|
Lexiva/Agenerase
|
27
|
(16)
|
15
|
(10)
|
8
|
(23)
|
2
|
(31)
|
1
|
5
|
|
Selzentry
|
37
|
28
|
13
|
4
|
15
|
11
|
2
|
>100
|
1
|
>100
|
|
Tivicay
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Trizivir
|
24
|
(11)
|
14
|
(7)
|
9
|
(15)
|
-
|
-
|
-
|
-
|
|
Other
|
28
|
(46)
|
12
|
(61)
|
8
|
(44)
|
5
|
(17)
|
1
|
(1)
|
|
Established products
|
1,003
|
(5)
|
328
|
(3)
|
195
|
(15)
|
316
|
6
|
143
|
(9)
|
|
Coreg
|
33
|
(9)
|
32
|
(9)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Hepsera
|
27
|
(7)
|
-
|
-
|
-
|
-
|
21
|
(5)
|
6
|
-
|
|
Imigran/Imitrex
|
48
|
9
|
22
|
47
|
17
|
(6)
|
2
|
100
|
6
|
(14)
|
|
Lamictal
|
133
|
(9)
|
66
|
(23)
|
28
|
(3)
|
19
|
12
|
18
|
33
|
|
Lovaza
|
148
|
(3)
|
147
|
(3)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Requip
|
31
|
(29)
|
2
|
(78)
|
15
|
(29)
|
4
|
33
|
10
|
(8)
|
|
Serevent
|
33
|
(13)
|
13
|
(8)
|
14
|
(18)
|
1
|
-
|
3
|
(20)
|
|
Seroxat/Paxil
|
73
|
(15)
|
-
|
-
|
14
|
-
|
23
|
10
|
32
|
(30)
|
|
Valtrex
|
55
|
(6)
|
11
|
57
|
7
|
(30)
|
9
|
13
|
26
|
(6)
|
|
Zeffix
|
57
|
(2)
|
3
|
50
|
3
|
(40)
|
47
|
2
|
4
|
-
|
|
Other
|
365
|
1
|
32
|
72
|
97
|
(15)
|
190
|
6
|
38
|
2
|
|
--------
|
----------
|
|||||||||
|
5,004
|
(2)
|
|||||||||
|
--------
|
----------
|
|||||||||
|
Total
|
USA
|
Europe
|
Emerging Markets
|
Japan
|
||
|
------------
|
----------
|
----------
|
----------
|
----------
|
||
|
£m
|
£m
|
£m
|
£m
|
£m
|
||
|
----------
|
----------
|
----------
|
----------
|
----------
|
||
|
Respiratory
|
7,044
|
3,331
|
1,789
|
815
|
604
|
|
|
Avamys/Veramyst
|
246
|
59
|
62
|
63
|
46
|
|
|
Flixotide/Flovent
|
779
|
448
|
122
|
55
|
55
|
|
|
Relvar/Breo
|
-
|
-
|
-
|
-
|
-
|
|
|
Seretide/Advair
|
5,046
|
2,533
|
1,447
|
417
|
309
|
|
|
Ventolin
|
631
|
277
|
126
|
171
|
11
|
|
|
Other
|
342
|
14
|
32
|
109
|
183
|
|
|
Oncology
|
798
|
321
|
256
|
131
|
56
|
|
|
Arzerra
|
60
|
38
|
21
|
-
|
-
|
|
|
Mekinist
|
-
|
-
|
-
|
-
|
-
|
|
|
Promacta
|
130
|
54
|
36
|
12
|
25
|
|
|
Tafinlar
|
-
|
-
|
-
|
-
|
-
|
|
|
Tyverb/Tykerb
|
239
|
68
|
87
|
54
|
22
|
|
|
Votrient
|
183
|
91
|
66
|
22
|
1
|
|
|
Other
|
186
|
70
|
46
|
43
|
8
|
|
|
Cardiovascular, metabolic and urology (CVMU)
|
1,144
|
620
|
251
|
109
|
110
|
|
|
Avodart
|
790
|
317
|
228
|
84
|
110
|
|
|
Other
|
354
|
303
|
23
|
25
|
-
|
|
|
Immuno-inflammation
|
70
|
65
|
4
|
-
|
-
|
|
|
Benlysta
|
70
|
65
|
4
|
-
|
-
|
|
|
Other
|
-
|
-
|
-
|
-
|
-
|
|
|
Other
|
2,630
|
345
|
676
|
1,147
|
257
|
|
|
Dermatology
|
680
|
181
|
155
|
279
|
33
|
|
|
Augmentin
|
608
|
1
|
202
|
367
|
16
|
|
|
Other anti-bacterials
|
233
|
7
|
60
|
158
|
3
|
|
|
Rare diseases
|
495
|
117
|
123
|
48
|
188
|
|
|
Other
|
614
|
39
|
136
|
295
|
17
|
|
|
Vaccines
|
3,325
|
826
|
980
|
1,107
|
176
|
|
|
Boostrix
|
238
|
147
|
53
|
16
|
-
|
|
|
Cervarix
|
270
|
6
|
53
|
75
|
132
|
|
|
Fluarix, FluLaval
|
200
|
88
|
43
|
44
|
-
|
|
|
Hepatitis
|
646
|
266
|
197
|
128
|
-
|
|
|
Infanrix, Pediarix
|
775
|
218
|
376
|
120
|
-
|
|
|
Rotarix
|
360
|
100
|
39
|
159
|
44
|
|
|
Synflorix
|
385
|
-
|
45
|
334
|
-
|
|
|
Other
|
451
|
1
|
174
|
231
|
-
|
|
|
----------
|
----------
|
----------
|
----------
|
----------
|
||
|
Innovative products
|
15,011
|
5,508
|
3,956
|
3,309
|
1,203
|
|
|
----------
|
----------
|
----------
|
----------
|
|||
|
ViiV Healthcare (HIV)
|
1,374
|
520
|
523
|
198
|
57
|
|
|
Combivir
|
179
|
24
|
64
|
79
|
4
|
|
|
Epzicom/Kivexa
|
665
|
243
|
285
|
57
|
36
|
|
|
Lexiva/Agenerase
|
127
|
68
|
33
|
19
|
3
|
|
|
Selzentry
|
128
|
57
|
56
|
4
|
3
|
|
|
Tivicay
|
-
|
-
|
-
|
-
|
-
|
|
|
Trizivir
|
107
|
61
|
37
|
5
|
-
|
|
|
Other
|
168
|
67
|
48
|
34
|
11
|
|
|
Established products
|
4,351
|
1,377
|
809
|
1,249
|
760
|
|
|
Coreg
|
133
|
132
|
-
|
-
|
-
|
|
|
Hepsera
|
126
|
-
|
-
|
95
|
31
|
|
|
Imigran/Imitrex
|
190
|
72
|
67
|
7
|
32
|
|
|
Lamictal
|
610
|
332
|
112
|
75
|
78
|
|
|
Lovaza
|
607
|
604
|
-
|
-
|
-
|
|
|
Requip
|
164
|
19
|
76
|
14
|
55
|
|
|
Serevent
|
145
|
51
|
64
|
3
|
20
|
|
|
Seroxat/Paxil
|
374
|
(1)
|
57
|
84
|
214
|
|
|
Valtrex
|
252
|
35
|
33
|
37
|
130
|
|
|
Zeffix
|
243
|
15
|
16
|
188
|
20
|
|
|
Other
|
1,507
|
118
|
384
|
746
|
180
|
|
|
----------
|
||||||
|
20,736
|
||||||
|
----------
|
|
Consumer Healthcare turnover
|
||
|
Twelve months ended 31 December 2013
|
||
|
£m
|
CER%
|
|
|
------
|
------
|
|
|
Wellness
|
1,865
|
(5)
|
|
Oral health
|
1,884
|
6
|
|
Nutrition
|
627
|
12
|
|
Skin health
|
380
|
6
|
|
------
|
------
|
|
|
Total
|
4,756
|
2
|
|
------
|
------
|
|
|
USA
|
951
|
1
|
|
Europe
|
1,392
|
(2)
|
|
ROW
|
2,413
|
5
|
|
------
|
------
|
|
|
Total
|
4,756
|
2
|
|
------
|
------
|
|
Consumer Healthcare turnover
|
||
|
Three months ended 31 December 2013
|
||
|
£m
|
CER%
|
|
|
------
|
------
|
|
|
Wellness
|
454
|
(6)
|
|
Oral health
|
447
|
4
|
|
Nutrition
|
130
|
11
|
|
Skin health
|
96
|
1
|
|
------
|
------
|
|
|
Total
|
1,127
|
-
|
|
------
|
------
|
|
|
USA
|
242
|
(2)
|
|
Europe
|
342
|
(4)
|
|
ROW
|
543
|
4
|
|
------
|
------
|
|
|
Total
|
1,127
|
-
|
|
------
|
------
|
|
Consumer Healthcare turnover
|
||
|
Three months ended 30 September 2013
|
||
|
£m
|
CER%
|
|
|
------
|
------
|
|
|
Wellness
|
464
|
(1)
|
|
Oral health
|
476
|
6
|
|
Nutrition
|
160
|
12
|
|
Skin health
|
90
|
11
|
|
------
|
------
|
|
|
Total
|
1,190
|
4
|
|
------
|
------
|
|
|
USA
|
233
|
-
|
|
Europe
|
353
|
4
|
|
ROW
|
604
|
6
|
|
------
|
------
|
|
|
Total
|
1,190
|
4
|
|
------
|
------
|
|
Consumer Healthcare turnover
|
|
Three months ended 30 June 2013
|
|
£m
|
CER%
|
|
|
------
|
------
|
|
|
Wellness
|
448
|
(8)
|
|
Oral health
|
481
|
8
|
|
Nutrition
|
162
|
14
|
|
Skin health
|
97
|
7
|
|
------
|
------
|
|
|
Total
|
1,188
|
2
|
|
------
|
------
|
|
USA
|
238
|
5
|
|
Europe
|
343
|
(3)
|
|
ROW
|
607
|
4
|
|
------
|
------
|
|
|
Total
|
1,188
|
2
|
|
------
|
------
|
|
Consumer Healthcare turnover
|
|
Three months ended 31 March 2013
|
|
£m
|
CER%
|
|
|
------
|
------
|
|
|
Wellness
|
499
|
(5)
|
|
Oral health
|
480
|
5
|
|
Nutrition
|
175
|
12
|
|
Skin health
|
97
|
6
|
|
------
|
------
|
|
|
Total
|
1,251
|
1
|
|
------
|
------
|
|
USA
|
238
|
3
|
|
Europe
|
354
|
(5)
|
|
ROW
|
659
|
5
|
|
------
|
------
|
|
|
Total
|
1,251
|
1
|
|
------
|
------
|
|
Consumer Healthcare turnover
|
|
Twelve months ended 31 December 2012
|
|
£m
|
|
|
------
|
|
|
Wellness
|
1,991
|
|
Oral health
|
1,806
|
|
Nutrition
|
590
|
|
Skin health
|
360
|
|
------
|
|
|
Total
|
4,747
|
|
------
|
|
USA
|
926
|
|
Europe
|
1,386
|
|
ROW
|
2,435
|
|
------
|
|
|
Total
|
4,747
|
|
------
|
|
Impact of Divestments on 2013 Core Results
|
|
FY 2013
|
||||
|
Reported
£m
|
Revised
£m
|
Change
£m
|
||
|
------
|
------
|
------
|
||
|
Turnover
|
26,505
|
25,602
|
(903)
|
|
|
Cost of sales
|
(7,549)
|
(7,075)
|
474
|
|
|
------
|
------
|
------
|
||
|
Gross profit
|
18,956
|
18,527
|
(429)
|
|
|
Selling, general and administration
|
(7,928)
|
(7,749)
|
179
|
|
|
Research and development
|
(3,400)
|
(3,394)
|
6
|
|
|
Royalty income
|
387
|
387
|
-
|
|
|
------
|
------
|
------
|
||
|
Operating profit
|
8,015
|
7,771
|
(244)
|
|
|
Net finance costs
|
(692)
|
(692)
|
-
|
|
|
Share of after tax profits of associates and joint ventures
|
43
|
43
|
-
|
|
|
------
|
------
|
------
|
||
|
Profit before taxation
|
7,366
|
7,122
|
(244)
|
|
|
Taxation
|
(1,695)
|
(1,635)
|
60
|
|
|
Tax rate%
|
23.0%
|
23.0%
|
||
|
------
|
------
|
------
|
||
|
Profit after taxation
|
5,671
|
5,487
|
(184)
|
|
|
------
|
------
|
------
|
||
|
Profit attributable to non-controlling interest
|
250
|
250
|
-
|
|
|
Profit attributable to shareholders
|
5,421
|
5,237
|
(184)
|
|
|
------
|
------
|
------
|
||
|
Earnings per share
|
112.2p
|
108.4p
|
(3.8)p
|
|
|
Weighted average number of shares
|
4,831
|
4,831
|
||
|
Reported 2013 Core Results
|
Q1 2013
£m
|
Q2 2013
£m
|
H1 2013
£m
|
Q3 2013
£m
|
9M 2013
£m
|
Q4 2013
£m
|
FY 2013
£m
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Turnover
|
6,471
|
6,618
|
13,089
|
6,510
|
19,599
|
6,906
|
26,505
|
|
Cost of sales
|
(1,847)
|
(1,818)
|
(3,665)
|
(1,878)
|
(5,543)
|
(2,006)
|
(7,549)
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Gross profit
|
4,624
|
4,800
|
9,424
|
4,632
|
14,056
|
4,900
|
18,956
|
|
Selling, general and administration
|
(1,955)
|
(2,092)
|
(4,047)
|
(1,876)
|
(5,923)
|
(2,005)
|
(7,928)
|
|
Research and development
|
(857)
|
(847)
|
(1,704)
|
(791)
|
(2,495)
|
(905)
|
(3,400)
|
|
Royalty income
|
113
|
82
|
195
|
94
|
289
|
98
|
387
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Operating profit
|
1,925
|
1,943
|
3,868
|
2,059
|
5,927
|
2,088
|
8,015
|
|
Net finance costs
|
(176)
|
(183)
|
(359)
|
(178)
|
(537)
|
(155)
|
(692)
|
|
Share of after tax profits of associates and joint ventures
|
11
|
7
|
18
|
14
|
32
|
11
|
43
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Profit before taxation
|
1,760
|
1,767
|
3,527
|
1,895
|
5,422
|
1,944
|
7,366
|
|
Taxation
|
(394)
|
(424)
|
(818)
|
(446)
|
(1,264)
|
(431)
|
(1,695)
|
|
Tax rate %
|
22.4%
|
24.0%
|
23.2%
|
23.5%
|
23.3%
|
22.2%
|
23.0%
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Profit after taxation
|
1,366
|
1,343
|
2,709
|
1,449
|
4,158
|
1,513
|
5,671
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Profit attributable to
non-controlling interests
|
68
|
64
|
132
|
49
|
181
|
69
|
250
|
|
Profit attributable to shareholders
|
1,298
|
1,279
|
2,577
|
1,400
|
3,977
|
1,444
|
5,421
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Earnings per share
|
26.9p
|
26.3p
|
53.2p
|
28.9p
|
82.1p
|
30.1p
|
112.2p
|
|
Weighted average number of shares
|
4,834
|
4,855
|
4,844
|
4,837
|
4,842
|
4,798
|
4,831
|
|
Impact of Divestments on 2013 Core Results
|
|
Q1 2013
£m
|
Q2 2013
£m
|
H1 2013
£m
|
Q3 2013
£m
|
9M 2013
£m
|
Q4 2013
£m
|
FY 2013
£m
|
||
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Turnover
|
(216)
|
(245)
|
(461)
|
(236)
|
(697)
|
(206)
|
(903)
|
|
|
Cost of sales
|
118
|
126
|
244
|
127
|
371
|
103
|
474
|
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Gross profit
|
(98)
|
(119)
|
(217)
|
(109)
|
(326)
|
(103)
|
(429)
|
|
|
Selling, general and administration
|
47
|
53
|
100
|
45
|
145
|
34
|
179
|
|
|
Research and development
|
2
|
1
|
3
|
2
|
5
|
1
|
6
|
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Operating profit
|
(49)
|
(65)
|
(114)
|
(62)
|
(176)
|
(68)
|
(244)
|
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Profit before taxation
|
(49)
|
(65)
|
(114)
|
(62)
|
(176)
|
(68)
|
(244)
|
|
|
Taxation
|
12
|
16
|
28
|
15
|
43
|
17
|
60
|
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Profit after taxation
|
(37)
|
(49)
|
(86)
|
(47)
|
(133)
|
(51)
|
(184)
|
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Profit attributable to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
Profit attributable to shareholders
|
(37)
|
(49)
|
(86)
|
(47)
|
(133)
|
(51)
|
(184)
|
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
||
|
Earnings per share
|
(3.8)p
|
|||||||
|
Weighted average number of shares
|
4,831
|
|
Revised 2013 Core Results
|
Q1 2013
£m
|
Q2 2013
£m
|
H1 2013
£m
|
Q3 2013
£m
|
9M 2013
£m
|
Q4 2013
£m
|
FY 2013
£m
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Turnover
|
6,255
|
6,373
|
12,628
|
6,274
|
18,902
|
6,700
|
25,602
|
|
Cost of sales
|
(1,729)
|
(1,692)
|
(3,421)
|
(1,751)
|
(5,172)
|
(1,903)
|
(7,075)
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Gross profit
|
4,526
|
4,681
|
9,207
|
4,523
|
13,730
|
4,797
|
18,527
|
|
Selling, general and administration
|
(1,908)
|
(2,039)
|
(3,947)
|
(1,831)
|
(5,778)
|
(1,971)
|
(7,749)
|
|
Research and development
|
(855)
|
(846)
|
(1,701)
|
(789)
|
(2,490)
|
(904)
|
(3,394)
|
|
Royalty income
|
113
|
82
|
195
|
94
|
289
|
98
|
387
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Operating profit
|
1,876
|
1,878
|
3,754
|
1,997
|
5,751
|
2,020
|
7,771
|
|
Net finance costs
|
(176)
|
(183)
|
(359)
|
(178)
|
(537)
|
(155)
|
(692)
|
|
Share of after tax profits of
associates and joint ventures
|
11
|
7
|
18
|
14
|
32
|
11
|
43
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Profit before taxation
|
1,711
|
1,702
|
3,413
|
1,833
|
5,246
|
1,876
|
7,122
|
|
Taxation
|
(382)
|
(408)
|
(790)
|
(431)
|
(1,221)
|
(414)
|
(1,635)
|
|
Tax rate %
|
22.3%
|
24.0%
|
23.1%
|
23.5%
|
23.3%
|
22.1%
|
23.0%
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Profit after taxation
|
1,329
|
1,294
|
2,623
|
1,402
|
4,025
|
1,462
|
5,487
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Profit attributable to
non-controlling interests
|
68
|
64
|
132
|
49
|
181
|
69
|
250
|
|
Profit attributable to shareholders
|
1,261
|
1,230
|
2,491
|
1,353
|
3,844
|
1,393
|
5,237
|
|
------
|
------
|
------
|
------
|
------
|
------
|
------
|
|
|
Earnings per share
|
26.1p
|
25.3p
|
51.4p
|
28.0p
|
79.4p
|
29.0p
|
108.4p
|
|
Weighted average number of shares
|
4,834
|
4,855
|
4,844
|
4,837
|
4,842
|
4,798
|
4,831
|
|
Three months ended 31 March 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
6,471
|
6,471
|
|||||
|
Cost of sales
|
(1,847)
|
(109)
|
(20)
|
(1,976)
|
|||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
4,624
|
(109)
|
(20)
|
4,495
|
|||
|
Selling, general and administration
|
(1,955)
|
(60)
|
(66)
|
1
|
(2,080)
|
||
|
Research and development
|
(857)
|
(25)
|
1
|
(6)
|
(17)
|
(904)
|
|
|
Royalty income
|
113
|
113
|
|||||
|
Other operating income/(expense)
|
(44)
|
(44)
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
1,925
|
(134)
|
1
|
(86)
|
(66)
|
(60)
|
1,580
|
|
Net finance costs
|
(176)
|
(2)
|
(2)
|
(180)
|
|||
|
Share of after tax profits of associates and joint ventures
|
11
|
11
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
1,760
|
(134)
|
1
|
(88)
|
(66)
|
(62)
|
1,411
|
|
Taxation
|
(394)
|
37
|
(57)
|
12
|
20
|
(382)
|
|
|
Tax rate %
|
22.4%
|
27.1%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
1,366
|
(97)
|
1
|
(145)
|
(54)
|
(42)
|
1,029
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
68
|
68
|
|||||
|
Profit attributable to shareholders
|
1,298
|
(97)
|
1
|
(145)
|
(54)
|
(42)
|
961
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
26.9p
|
(2.0)p
|
-
|
(3.0)p
|
(1.1)p
|
(0.9)p
|
19.9p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,834
|
4,834
|
|||||
|
------------
|
------------
|
|
Three months ended 30 June 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
6,618
|
6,618
|
|||||
|
Cost of sales
|
(1,818)
|
(109)
|
(45)
|
(1,972)
|
|||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
4,800
|
(109)
|
(45)
|
4,646
|
|||
|
Selling, general and administration
|
(2,092)
|
(99)
|
(24)
|
(1)
|
(2,216)
|
||
|
Research and development
|
(847)
|
(24)
|
(135)
|
(29)
|
(14)
|
(1,049)
|
|
|
Royalty income
|
82
|
82
|
|||||
|
Other operating income/(expense)
|
(25)
|
(25)
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
1,943
|
(133)
|
(135)
|
(173)
|
(24)
|
(40)
|
1,438
|
|
Net finance costs
|
(183)
|
(1)
|
(2)
|
(186)
|
|||
|
Profit on disposal of associates
|
29
|
29
|
|||||
|
Share of after tax profits of associates and joint ventures
|
7
|
7
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
1,767
|
(133)
|
(135)
|
(174)
|
(24)
|
(13)
|
1,288
|
|
Taxation
|
(424)
|
36
|
35
|
135
|
14
|
(204)
|
|
|
Tax rate %
|
24.0%
|
15.8%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
1,343
|
(97)
|
(100)
|
(39)
|
(24)
|
1
|
1,084
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
64
|
(25)
|
39
|
||||
|
Profit attributable to shareholders
|
1,279
|
(97)
|
(100)
|
(39)
|
(24)
|
26
|
1,045
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
26.3p
|
(2.0)p
|
(2.1)p
|
(0.8)p
|
(0.5)p
|
0.6p
|
21.5p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,855
|
4,855
|
|||||
|
------------
|
------------
|
|
Six months ended 30 June 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
13,089
|
13,089
|
|||||
|
Cost of sales
|
(3,665)
|
(218)
|
(65)
|
(3,948)
|
|||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
9,424
|
(218)
|
(65)
|
9,141
|
|||
|
Selling, general and administration
|
(4,047)
|
(159)
|
(90)
|
(4,296)
|
|||
|
Research and development
|
(1,704)
|
(49)
|
(134)
|
(35)
|
(31)
|
(1,953)
|
|
|
Royalty income
|
195
|
195
|
|||||
|
Other operating income/(expense)
|
(69)
|
(69)
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
3,868
|
(267)
|
(134)
|
(259)
|
(90)
|
(100)
|
3,018
|
|
Net finance costs
|
(359)
|
(3)
|
(4)
|
(366)
|
|||
|
Profit on disposal of associates
|
29
|
29
|
|||||
|
Share of after tax profits
of associates and joint ventures
|
18
|
18
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
3,527
|
(267)
|
(134)
|
(262)
|
(90)
|
(75)
|
2,699
|
|
Taxation
|
(818)
|
73
|
35
|
78
|
12
|
34
|
(586)
|
|
Tax rate %
|
23.2%
|
21.7%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
2,709
|
(194)
|
(99)
|
(184)
|
(78)
|
(41)
|
2,113
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
132
|
(25)
|
107
|
||||
|
Profit attributable to
shareholders
|
2,577
|
(194)
|
(99)
|
(184)
|
(78)
|
(16)
|
2,006
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
53.2p
|
(4.0)p
|
(2.0)p
|
(3.8)p
|
(1.6)p
|
(0.4)p
|
41.4p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,844
|
4,844
|
|||||
|
------------
|
------------
|
|
Three months ended 30 September 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting
and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
6,510
|
6,510
|
|||||
|
Cost of sales
|
(1,878)
|
(105)
|
(81)
|
(47)
|
(2,111)
|
||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
4,632
|
(105)
|
(81)
|
(47)
|
4,399
|
||
|
Selling, general and administration
|
(1,876)
|
(34)
|
(73)
|
(1)
|
(1,984)
|
||
|
Research and development
|
(791)
|
(25)
|
(71)
|
(2)
|
(11)
|
(900)
|
|
|
Royalty income
|
94
|
94
|
|||||
|
Other operating income/(expense)
|
-
|
(40)
|
(40)
|
||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
2,059
|
(130)
|
(152)
|
(83)
|
(73)
|
(52)
|
1,569
|
|
Net finance costs
|
(178)
|
(1)
|
(2)
|
(181)
|
|||
|
Share of after tax profits of associates and joint ventures
|
14
|
14
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
1,895
|
(130)
|
(152)
|
(84)
|
(73)
|
(54)
|
1,402
|
|
Taxation
|
(446)
|
35
|
37
|
(43)
|
14
|
11
|
(392)
|
|
Tax rate %
|
23.5%
|
28.0%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
1,449
|
(95)
|
(115)
|
(127)
|
(59)
|
(43)
|
1,010
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
49
|
(8)
|
41
|
||||
|
Profit attributable to
shareholders
|
1,400
|
(95)
|
(115)
|
(127)
|
(59)
|
(35)
|
969
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
28.9p
|
(2.0)p
|
(2.4)p
|
(2.6)p
|
(1.2)p
|
(0.7)p
|
20.0p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,837
|
4,837
|
|||||
|
------------
|
------------
|
|
Nine months ended 30 September 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting
and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
19,599
|
19,599
|
|||||
|
Cost of sales
|
(5,543)
|
(323)
|
(81)
|
(112)
|
(6,059)
|
||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
14,056
|
(323)
|
(81)
|
(112)
|
13,540
|
||
|
Selling, general and administration
|
(5,923)
|
(193)
|
(163)
|
(1)
|
(6,280)
|
||
|
Research and development
|
(2,495)
|
(74)
|
(205)
|
(37)
|
(42)
|
(2,853)
|
|
|
Royalty income
|
289
|
289
|
|||||
|
Other operating income/(expense)
|
-
|
(109)
|
(109)
|
||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
5,927
|
(397)
|
(286)
|
(342)
|
(163)
|
(152)
|
4,587
|
|
Net finance costs
|
(537)
|
(4)
|
(6)
|
(547)
|
|||
|
Profit on disposal of associates and joint ventures
|
-
|
29
|
29
|
||||
|
Share of after tax profits of associates and joint ventures
|
32
|
32
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
5,422
|
(397)
|
(286)
|
(346)
|
(163)
|
(129)
|
4,101
|
|
Taxation
|
(1,264)
|
108
|
72
|
35
|
26
|
45
|
(978)
|
|
Tax rate %
|
23.3%
|
23.8%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
4,158
|
(289)
|
(214)
|
(311)
|
(137)
|
(84)
|
3,123
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
181
|
(33)
|
148
|
||||
|
Profit attributable to shareholders
|
3,977
|
(289)
|
(214)
|
(311)
|
(137)
|
(51)
|
2,975
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
82.1p
|
(6.1)p
|
(4.4)p
|
(6.4)p
|
(2.8)p
|
(1.0)p
|
61.4p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,842
|
4,842
|
|||||
|
------------
|
------------
|
|
Three months ended 31 December 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting
and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
6,906
|
6,906
|
|||||
|
Cost of sales
|
(2,006)
|
(127)
|
(327)
|
(66)
|
(2,526)
|
||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
4,900
|
(127)
|
(327)
|
(66)
|
4,380
|
||
|
Selling, general and administration
|
(2,005)
|
(107)
|
(89)
|
1
|
(2,200)
|
||
|
Research and development
|
(905)
|
(23)
|
(126)
|
(2)
|
(14)
|
(1,070)
|
|
|
Royalty income
|
98
|
98
|
|||||
|
Other operating income/(expense)
|
1,233
|
1,233
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
2,088
|
(150)
|
(453)
|
(175)
|
(89)
|
1,220
|
2,441
|
|
Net finance costs
|
(155)
|
(2)
|
(2)
|
(159)
|
|||
|
Profit on disposal of associates and joint ventures
|
-
|
253
|
253
|
||||
|
Share of after tax profits of associates and joint ventures
|
11
|
11
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
1,944
|
(150)
|
(453)
|
(177)
|
(89)
|
1,471
|
2,546
|
|
Taxation
|
(431)
|
41
|
154
|
110
|
(17)
|
102
|
(41)
|
|
Tax rate %
|
22.2%
|
1.6%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
1,513
|
(109)
|
(299)
|
(67)
|
(106)
|
1,573
|
2,505
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
69
|
(25)
|
44
|
||||
|
Profit attributable to
shareholders
|
1,444
|
(109)
|
(299)
|
(67)
|
(106)
|
1,598
|
2,461
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
30.1p
|
(2.3)p
|
(6.2)p
|
(1.4)p
|
(2.2)p
|
33.3p
|
51.3p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,798
|
4,798
|
|||||
|
------------
|
------------
|
|
Year ended 31 December 2013
|
|
Core
results
£m
|
Intangible
amortisation
£m
|
Intangible
impairment
£m
|
Major
restructuring
£m
|
Legal
costs
£m
|
Acquisition
accounting
and other
£m
|
Total
results
£m
|
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Turnover
|
26,505
|
26,505
|
|||||
|
Cost of sales
|
(7,549)
|
(450)
|
(408)
|
(178)
|
(8,585)
|
||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Gross profit
|
18,956
|
(450)
|
(408)
|
(178)
|
-
|
17,920
|
|
|
Selling, general and administration
|
(7,928)
|
(300)
|
(252)
|
(8,480)
|
|||
|
Research and development
|
(3,400)
|
(97)
|
(331)
|
(39)
|
(56)
|
(3,923)
|
|
|
Royalty income
|
387
|
387
|
|||||
|
Other operating income/(expense)
|
-
|
1,124
|
1,124
|
||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Operating profit
|
8,015
|
(547)
|
(739)
|
(517)
|
(252)
|
1,068
|
7,028
|
|
Net finance costs
|
(692)
|
(6)
|
(8)
|
(706)
|
|||
|
Profit on disposal of interest in associates and joint ventures
|
-
|
282
|
282
|
||||
|
Share of after tax profits of associates and joint ventures
|
43
|
43
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit before taxation
|
7,366
|
(547)
|
(739)
|
(523)
|
(252)
|
1,342
|
6,647
|
|
Taxation
|
(1,695)
|
149
|
226
|
145
|
9
|
147
|
(1,019)
|
|
Tax rate %
|
23.0%
|
15.3%
|
|||||
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit after taxation
|
5,671
|
(398)
|
(513)
|
(378)
|
(243)
|
1,489
|
5,628
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Profit attributable to non-controlling interests
|
250
|
(58)
|
192
|
||||
|
Profit attributable to shareholders
|
5,421
|
(398)
|
(513)
|
(378)
|
(243)
|
1,547
|
5,436
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Earnings per share
|
112.2p
|
(8.2)p
|
(10.7)p
|
(7.8)p
|
(5.0)p
|
32.0p
|
112.5p
|
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
------------
|
|
|
Weighted average number of shares (millions)
|
4,831
|
4,831
|
|||||
|
------------
|
------------
|